Clinical-stage Redx Pharma, Jounce Therapeutics sign $425m merger deal
Redx Pharma, a UK-based clinical-stage biotechnology company, and Jounce Therapeutics, a Nasdaq-listed clinical-stage immunotherapy company, have agreed to merge in an all-stock deal that values the combined group at $425 million. The combined group will operate as Redx Inc., which will trade on Nasdaq under the ticker REDX. It will be led by the incumbent […]